Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of RA for at least 3 months prior to screening~* Have no history of latent or active tuberculosis (TB) and test negative for TB~Exclusion Criteria:~* Have inflammatory diseases other than RA~* Have been treated with disease-modifying anti-rheumatic drugs (DMARDs)/systemic immunosuppressives other than methotrexate (MTX), sulfasalazine, or hydroxychloroquine during the 4 weeks prior to the first administration of study agent~* Have received intramuscular (IM), IV, or intra-articular corticosteroids within 4 weeks of study agent administration~* Have a known hypersensitivity to human Ig proteins~* Have received infliximab, golimumab, adalimumab or abatacept within 3 months, or etanercept or anakinra within 1 month prior to the first administration of study agent~* Have received alefacept, efalizumab, natalizumab, rituximab, or any B-cell-depleting agent~* Have been treated with any other biologics or investigational drugs, within 5 half-lives of that drug prior to the first administration of study agent~* Have a history of latent or active granulomatous infection, including tuberculosis (TB), histoplasmosis, or coccidioidomycosis, prior to screening~* Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening~* Have had a serious infection (eg, hepatitis, pneumonia, pyelonephritis, or sepsis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Golimumab IV infusions of 2 mg/kg golimumab on Days 1 and 85.
- 002 (Type: EXPERIMENTAL): Golimumab SC injection of 100 mg every 4 weeks through Week 20

Based on this trial design, predict the completion outcome and termination type (if applicable).